Literature DB >> 21701995

Neuroprotection by human umbilical cord blood-derived progenitors in ischemic brain injuries.

Hadar Arien-Zakay1, Shimon Lecht, Armon Nagler, Philip Lazarovici.   

Abstract

Stem cells have an extremely high potential to treat many devastating diseases, including neuronal injuries. Albeit the need for human neuronal stem cells, their quantities are very limited by relying on early human embryos as the main source. Therefore, progenitors of other origins, such as human umbilical cord blood (CB) are being considered. In the last decade, various populations isolated from the CB were reported to differentiate in vitro towards a neural phenotype. The conditions to induce the cell differentiation are not conclusive and may include addition of chemicals, cytokines and growth factors, including the nerve growth factor (NGF). Some CB cells were found to express the TrkANGF receptor, suggesting an endogenous role for this growth factor also in the CB environment. The ability of CB and derived stem cell populations to protect against neurological deficits was shown, both in vitro and in vivo, in models of ischemic brain injuries. In rodent models of stroke, heatstroke, brain trauma and brain damage at birth, CB cells either by intravenous injection or intrastriatal transplantation, were found to reduce the infarct size and the neurological deficits caused by the injury. The restorative effects of CB were suggested to be mediated by mechanisms other than cell replacement. Some of the proposed mechanisms involve reduced inflammation, nerve fiber reorganization by trophic actions, increased cell survival and enhanced angiogenesis. Furthermore, treatment with CB was found to have a therapeutic window of days compared with the present 36 hour window for the treatment of stroke with clinically available tools such as recombinant tissue plasminogen activator. Considering the encouraging results with whole CB and derived cells transplantation in ischemic injury models and since CB is widely available and have been used clinically, they may be an excellent source of cells for treatment of human brain ischemic disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21701995     DOI: 10.4449/aib.v149i2.1370

Source DB:  PubMed          Journal:  Arch Ital Biol        ISSN: 0003-9829            Impact factor:   1.000


  10 in total

1.  Intravenous administration of human umbilical cord blood-derived AC133+ endothelial progenitor cells in rat stroke model reduces infarct volume: magnetic resonance imaging and histological findings.

Authors:  Asm Iskander; Robert A Knight; Zheng Gang Zhang; James R Ewing; Adarsh Shankar; Nadimpalli Ravi S Varma; Hassan Bagher-Ebadian; Meser M Ali; Ali S Arbab; Branislava Janic
Journal:  Stem Cells Transl Med       Date:  2013-08-09       Impact factor: 6.940

Review 2.  Repairing neural injuries using human umbilical cord blood.

Authors:  Tao Sun; Quan-Hong Ma
Journal:  Mol Neurobiol       Date:  2012-12-30       Impact factor: 5.590

3.  Combination treatment of stroke with sub-therapeutic doses of Simvastatin and human umbilical cord blood cells enhances vascular remodeling and improves functional outcome.

Authors:  X Cui; M Chopp; A Zacharek; J Dai; C Zhang; T Yan; R Ning; C Roberts; A Shehadah; N Kuzmin-Nichols; C D Sanberg; J Chen
Journal:  Neuroscience       Date:  2012-10-04       Impact factor: 3.590

4.  Antiepileptic and neuroprotective effects of human umbilical cord blood mononuclear cells in a pilocarpine-induced epilepsy model.

Authors:  Zaquer Suzana Munhoz Costa-Ferro; Fernanda de Borba Cunha; Bruno Solano de Freitas Souza; Marcos Maurício Tosta Leal; Adelson Alves da Silva; Telma Ingrid Borges de Bellis Kühn; Andresa Forte; Eliseo Joji Sekiya; Milena Botelho Pereira Soares; Ricardo Ribeiro Dos Santos
Journal:  Cytotechnology       Date:  2013-08-09       Impact factor: 2.058

5.  Secretome of Differentiated PC12 Cells Restores the Monocrotophos-Induced Damages in Human Mesenchymal Stem Cells and SHSY-5Y Cells: Role of Autophagy and Mitochondrial Dynamics.

Authors:  A Srivastava; S Singh; C S Rajpurohit; P Srivastava; A Pandey; D Kumar; V K Khanna; A B Pant
Journal:  Neuromolecular Med       Date:  2018-03-30       Impact factor: 3.843

6.  Intracardiac Injection of Dental Pulp Stem Cells After Neonatal Hypoxia-Ischemia Prevents Cognitive Deficits in Rats.

Authors:  Eduardo Farias Sanches; Lauren Valentim; Felipe de Almeida Sassi; Lisiane Bernardi; Nice Arteni; Simone Nardin Weis; Felipe Kawa Odorcyk; Patricia Pranke; Carlos Alexandre Netto
Journal:  Neurochem Res       Date:  2018-09-25       Impact factor: 3.996

7.  Maximizing neuroprotection: where do we stand?

Authors:  Damien P Kuffler
Journal:  Ther Clin Risk Manag       Date:  2012-04-10       Impact factor: 2.423

8.  Therapeutic effect of nerve growth factor on cerebral infarction in dogs using the hemisphere anomalous volume ratio of diffusion-weighted magnetic resonance imaging.

Authors:  Yong Wang; Hui Zhang; Zhe Wang; Zuojun Geng; Huaijun Liu; Haiqing Yang; Peng Song; Qing Liu
Journal:  Neural Regen Res       Date:  2012-08-25       Impact factor: 5.135

9.  Drug- and cell-based therapies for targeting neuroinflammation in traumatic brain injury.

Authors:  Sussannah Kaelber; Paolina Pantcheva; Cesar V Borlongan
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

Review 10.  Neurorestorative therapy for stroke.

Authors:  Jieli Chen; Poornima Venkat; Alex Zacharek; Michael Chopp
Journal:  Front Hum Neurosci       Date:  2014-06-27       Impact factor: 3.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.